Clinical Trial Update: Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating cabozantinib in combination with pembrolizumab for locally advanced, metastatic, or unresectable adrenal cortical carcinoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenal Cortical Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• cabozantinib (cabozantinib)

Snippet

Sponsor: Emory University | Conditions: Locally Advanced Adrenal Cortex Carcinoma, Adrenal Cortical Carcinoma | Phase 2 | Status: RECRUITING